CellSave

What CellSave does

CellSave Arabia is a private, for-profit stem cell banking company headquartered in Dubai, United Arab Emirates, founded in 2005 and operating with 51-100 employees. The company collects, processes, and stores perinatal biological materials — including umbilical cord blood, cord tissue, placenta tissue, amnion tissue, and cord vessels — and more recently expanded into perinatal exosome banking. Its customers are expecting parents and families in the UAE and broader GCC/Middle East region who elect to preserve newborn biological samples for potential future medical use, including treatment of genetic disorders, blood diseases, and regenerative medicine applications.

The core product portfolio comprises eight service lines anchored by cord blood banking and cord tissue banking as flagship offerings, with add-on modules for amnion tissue, placenta tissue, cord vessel, and perinatal exosome preservation. Operationally, the company runs a cryopreservation and cellular therapy infrastructure that in 2024 became the first in the GCC to earn AABB (American Association of Blood Banks) accreditation for cellular therapy activities, a regulatory milestone it publicly highlights as a competitive differentiator.

CellSave generates revenue through a one-time collection fee per service line combined with recurring annual storage fees, giving it a subscription-style recurring revenue tail once samples are banked. The go-to-market is direct-to-consumer, supported by an educational blog covering pregnancy health and stem cell science, SEO-optimized landing pages (e.g., 'Cord Blood Banking UAE'), a featured-mom testimonial program, and earned media coverage in Forbes, Health Magazine, and Khaleej Times. Service delivery is fully bilingual in English and Arabic, and the company has signaled plans to extend its footprint with additional stem cell laboratories across the region.

Name

CellSave

Legal name

CellSave Arabia

Website

https://cellsave.ae

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

CellSave Arabia is a UAE-based stem cell bank that collects, processes, and stores perinatal biological samples (cord blood, cord tissue, placenta, amnion, exosomes) for expecting parents and families across the GCC, earning recurring storage fees under a direct-to-consumer subscription model.

Ownership category

akta.pro rank

Product category

Stem Cell Banking Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Stem cell banking
• Cord blood banking
• Cord tissue storage
• Perinatal tissue preservation
• Regenerative medicine services

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Operations, Infrastructure, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Stem Cell Banking Services: One-time collection fee followed by recurring annual storage fees for cord blood, cord tissue, placenta tissue, and amnion tissue banking. The company offers long-term storage services with annual renewal billing.
2. Perinatal Exosome Banking: Premium service for banking perinatal exosomes as part of expanded service offerings beyond traditional stem cell banking.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CellSave Arabia collects, processes, and cryogenically stores perinatal biological materials — including umbilical cord blood, cord tissue, placenta tissue, amnion tissue, and cord vessels — for expecting parents and families across the UAE and GCC region. The company has expanded into perinatal exosome banking and provides associated regenerative medicine services, operating as the first AABB-accredited stem cell bank in the GCC.

Product overview

CellSave is a stem cell banking company offering a comprehensive portfolio of perinatal tissue and cell preservation services. The core offerings include cord blood banking, cord tissue banking, and stem cell banking, with additional specialized services such as amnion tissue banking, placenta tissue banking, cord vessel banking, and perinatal exosome banking. The company operates as a unified service platform where families can preserve various biological materials from childbirth for potential future medical use in treating genetic disorders and regenerative medicine applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Cord Blood Banking Stem cell banking service that collects and stores blood from the umbilical cord after childbirth, preserving hematopoietic stem cells for potential future medical use in treating genetic disorders, blood diseases, and regenerative medicine applications. Targeted at expecting parents and families seeking biological insurance at birth.
• Cord Tissue Banking Service that collects and stores umbilical cord tissue containing mesenchymal stem cells, which are different from the stem cells found in cord blood and useful for distinct therapeutic applications. Targeted at families seeking comprehensive newborn stem cell preservation.
• Amnion Tissue Banking Preservation service for amnion tissue, a component of the amniotic membrane that may have regenerative properties and therapeutic applications. Targeted at expecting parents seeking comprehensive perinatal tissue preservation.
• Placenta Tissue Banking Service for storing placenta tissue, providing an additional source of valuable stem cells and regenerative tissues for potential therapeutic applications. Targeted at expecting families seeking comprehensive newborn tissue preservation.
• Cord Vessel Banking Service for banking blood vessels from the umbilical cord for potential future medical use. Targeted at expecting parents seeking specialized preservation of vascular perinatal tissues.
• Perinatal Exosome Banking Advanced service for banking exosomes derived from perinatal tissues, representing an expansion beyond traditional stem cell storage into novel regenerative medicine applications. Targeted at expecting families interested in cutting-edge biological preservation options.
• Regenerative Medicine Services Services related to the application of stored stem cells and tissues for regenerative medicine treatments. Targeted at families who have banked perinatal tissues with CellSave and may require future therapeutic access.

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves3 records

Expansion highlights5 records

Direct peers

• Cells4Life: One of the UK's largest private stem cell banks offering cord blood and tissue storage with a multi-sample processing platform. Direct comparison to CellSave given overlapping product lines, consumer target, and subscription storage model.
• Americord Registry: US private cord blood, cord tissue, and placenta tissue bank serving expecting parents directly. Highly comparable product mix and DTC model, useful for benchmarking US pricing and conversion benchmarks against CellSave.
• Smart Cells International: UK-based private cord blood and tissue stem cell bank offering cord blood, cord tissue, and placenta banking to expecting parents globally. Highly comparable to CellSave in service scope, DTC go-to-market, and recurring storage fee model.
• Precious Cells (now part of BioVault): UK private stem cell bank offering cord blood and tissue storage to parents. Comparable to CellSave in product scope and direct-to-consumer target customer, useful as a European private-bank benchmark.

Broad incumbents

• Cryo-Cell International: US-listed public stem cell bank offering cord blood and menstrual stem cell banking. Comparable in core cord blood banking and recurring storage revenue model, with longer public-company track record as a benchmark.
• CBR (Cord Blood Registry): One of the largest US private cord blood banks, acquired by CooperCompanies. Highly relevant as a scaled benchmark for service portfolio, marketing, and recurring storage economics in private stem cell banking.
• ViaCord: US private cord blood and cord tissue bank owned by Revvity (formerly PerkinElmer). Comparable to CellSave in offering structure and target customer, but at much larger US scale with greater product breadth.
• Cryo-Save (Esperite): European-headquartered family stem cell bank with a multi-country footprint including the Middle East. Comparable to CellSave in core service but operates at significantly larger scale across multiple jurisdictions.

Regional players

• BioCell Lebanon: Lebanese stem cell bank operating across the Middle East with similar cord blood and tissue banking services. Regional peer that competes for the same Arab-speaking expecting parent demographic in adjacent GCC and Levant markets.
• Virgin Health Bank QSTP-LLC: Qatar-based stem cell bank (associated with the Virgin brand) that operated across the GCC and MENA. Closest regional analog to CellSave in terms of geography and target market, though operating status should be verified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks1 record

Key highlights7 records

Customer concentration

• Xx.com/cellsavearabia
• Facebookfacebook.com/cellsavearabia
• LinkedInlinkedin.com/company/cellsavearabia

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellSave